Related Experiment Video
Updated: Feb 13, 2026

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
Published on: March 9, 2019
A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1
Yumi Matsui1, Isao Yasumatsu1, Ken Ichi Yoshida2
1Daiichi Sankyo RD Novare Co. Ltd, 1-16-13 Kita-Kasai, Edogawa-ku, Tokyo 134-8630, Japan.
Abstract:
Mitogen-activated protein kinase (MAPK)-interacting kinases 1 (Mnk1) and 2 (Mnk2) modulate translation initiation through the phosphorylation of eukaryotic translation initiation factor 4E, which promotes tumorigenesis. However, Mnk1 and Mnk2 are dispensable in normal cells, suggesting that the inhibition of Mnk1 and Mnk2 could be effective in cancer therapy. To provide a structural basis for Mnk1 inhibition, a novel Mnk1 inhibitor was discovered and the crystal structure of Mnk1 in complex with this inhibitor was determined. The crystal structure revealed that the inhibitor binds to the autoinhibited state of Mnk1, stabilizing the Mnk-specific DFD motif in the DFD-out conformation, thus preventing Mnk1 from switching to the active conformation and thereby inhibiting the kinase activity. These results provide a valuable platform for the structure-guided design of Mnk1 inhibitors.
Insights
Mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (Mnk1/2) drive cancer by affecting translation initiation. A novel inhibitor stabilizes Mnk1 in its inactive form, blocking cancer cell growth.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- Mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (Mnk1/2) regulate translation initiation via eukaryotic translation initiation factor 4E phosphorylation.
- Mnk1/2 activity is crucial for tumorigenesis but not essential for normal cell function, indicating therapeutic potential.
Purpose of the Study:
- To elucidate the structural basis for Mnk1 inhibition.
- To guide the development of novel Mnk1-targeted cancer therapies.
Main Methods:
- Discovery of a novel Mnk1 inhibitor.
- Determination of the crystal structure of Mnk1 in complex with the inhibitor.
Main Results:
- The inhibitor binds to the autoinhibited state of Mnk1.
- Stabilization of the Mnk-specific DFD motif in the DFD-out conformation.
- Prevention of Mnk1 activation and inhibition of kinase activity.
Conclusions:
- The identified inhibitor effectively blocks Mnk1 activity by stabilizing its autoinhibited conformation.
- These findings offer a structural foundation for designing potent Mnk1 inhibitors for cancer treatment.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Conformity
MAPK Signaling Cascades
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Nuclear Stability
To hold positively charged protons together...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

